- Home
- BEAT vs LITS Comparison
BEAT vs LITS Comparison
Compare BEAT & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BEAT | LITS |
|---|---|---|
| Founded | 2015 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.1M | 25.7M |
| IPO Year | 2021 | 2003 |
Fundamental Metrics
Financial Performance| Metric | BEAT | LITS |
|---|---|---|
| Price | $0.43 | $1.22 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $3.50 | N/A |
| AVG Volume (30 Days) | ★ 16.5M | 930.1K |
| Earning Date | 11-12-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.07 | 13.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,197.12 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.36 | $0.69 |
| 52 Week High | $4.00 | $2.26 |
Technical Indicators
Market Signals| Indicator | BEAT | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 46.56 | 49.21 |
| Support Level | $0.37 | $1.06 |
| Resistance Level | $0.52 | $1.25 |
| Average True Range (ATR) | 0.07 | 0.11 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 11.41 | 13.51 |
Price Performance
Historical ComparisonAbout BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.
About LITS Lite Strategy Inc.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.